Pathogenesis and therapeutic strategy in platinum resistance lung cancer
Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents in clinical use both of lung cancer in mono-and combination therapies. However, platinum resistance limits its clinical application. It is necessary to understand the molecular mechanism of platinum resistance...
Gespeichert in:
| Veröffentlicht in: | Biochimica et biophysica acta. Reviews on cancer 2021-08, Vol.1876 (1), p.188577-188577, Article 188577 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 188577 |
|---|---|
| container_issue | 1 |
| container_start_page | 188577 |
| container_title | Biochimica et biophysica acta. Reviews on cancer |
| container_volume | 1876 |
| creator | Lv, Panpan Man, Shuli Xie, Lu Ma, Long Gao, Wenyuan |
| description | Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents in clinical use both of lung cancer in mono-and combination therapies. However, platinum resistance limits its clinical application. It is necessary to understand the molecular mechanism of platinum resistance, identify predictive markers, and develop newer, more effective and less toxic agents to treat platinum resistance in lung cancer. Here, it summarizes the main molecular mechanisms associated with platinum resistance in lung cancer and the development of new approaches to tackle this clinically relevant problem. Moreover, it could lead to the development of more effective treatment for refractory lung cancer in future. |
| doi_str_mv | 10.1016/j.bbcan.2021.188577 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2539209401</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304419X21000743</els_id><sourcerecordid>2539209401</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-26972e94cfd7bbc7d5a29a622b2a63ca1bdf86f6fe8c73abc293466c4ed1fd903</originalsourceid><addsrcrecordid>eNp9kD9PwzAQxS0EEqXwCVg8siT4T-LEAwOqgCJVggEkNsuxL62r1Am2g8S3J6HMTHfDe-_u_RC6piSnhIrbfd40RvucEUZzWtdlVZ2gBa0rmbFS0FO0IJwUWUHlxzm6iHFPCC05Fwu0ftVp12_BQ3QRa29x2kHQA4zJGRxT0Am239h5PHQ6OT8ecJilSXsDuBv9Fpt5DZforNVdhKu_uUTvjw9vq3W2eXl6Xt1vMjPdSxkTsmIgC9Paavq5sqVmUgvGGqYFN5o2tq1FK1qoTcV1Y5jkhRCmAEtbKwlfoptj7hD6zxFiUgcXDXSd9tCPUbGSS0ZkQegk5UepCX2MAVo1BHfQ4VtRomZuaq9-uamZmzpym1x3RxdMLb4cBBWNg6midQFMUrZ3__p_AFFWeMs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2539209401</pqid></control><display><type>article</type><title>Pathogenesis and therapeutic strategy in platinum resistance lung cancer</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lv, Panpan ; Man, Shuli ; Xie, Lu ; Ma, Long ; Gao, Wenyuan</creator><creatorcontrib>Lv, Panpan ; Man, Shuli ; Xie, Lu ; Ma, Long ; Gao, Wenyuan</creatorcontrib><description>Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents in clinical use both of lung cancer in mono-and combination therapies. However, platinum resistance limits its clinical application. It is necessary to understand the molecular mechanism of platinum resistance, identify predictive markers, and develop newer, more effective and less toxic agents to treat platinum resistance in lung cancer. Here, it summarizes the main molecular mechanisms associated with platinum resistance in lung cancer and the development of new approaches to tackle this clinically relevant problem. Moreover, it could lead to the development of more effective treatment for refractory lung cancer in future.</description><identifier>ISSN: 0304-419X</identifier><identifier>EISSN: 1879-2561</identifier><identifier>DOI: 10.1016/j.bbcan.2021.188577</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Chemoresistance ; Lung cancer ; Platinum ; Therapy</subject><ispartof>Biochimica et biophysica acta. Reviews on cancer, 2021-08, Vol.1876 (1), p.188577-188577, Article 188577</ispartof><rights>2021 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c336t-26972e94cfd7bbc7d5a29a622b2a63ca1bdf86f6fe8c73abc293466c4ed1fd903</citedby><cites>FETCH-LOGICAL-c336t-26972e94cfd7bbc7d5a29a622b2a63ca1bdf86f6fe8c73abc293466c4ed1fd903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbcan.2021.188577$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids></links><search><creatorcontrib>Lv, Panpan</creatorcontrib><creatorcontrib>Man, Shuli</creatorcontrib><creatorcontrib>Xie, Lu</creatorcontrib><creatorcontrib>Ma, Long</creatorcontrib><creatorcontrib>Gao, Wenyuan</creatorcontrib><title>Pathogenesis and therapeutic strategy in platinum resistance lung cancer</title><title>Biochimica et biophysica acta. Reviews on cancer</title><description>Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents in clinical use both of lung cancer in mono-and combination therapies. However, platinum resistance limits its clinical application. It is necessary to understand the molecular mechanism of platinum resistance, identify predictive markers, and develop newer, more effective and less toxic agents to treat platinum resistance in lung cancer. Here, it summarizes the main molecular mechanisms associated with platinum resistance in lung cancer and the development of new approaches to tackle this clinically relevant problem. Moreover, it could lead to the development of more effective treatment for refractory lung cancer in future.</description><subject>Chemoresistance</subject><subject>Lung cancer</subject><subject>Platinum</subject><subject>Therapy</subject><issn>0304-419X</issn><issn>1879-2561</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kD9PwzAQxS0EEqXwCVg8siT4T-LEAwOqgCJVggEkNsuxL62r1Am2g8S3J6HMTHfDe-_u_RC6piSnhIrbfd40RvucEUZzWtdlVZ2gBa0rmbFS0FO0IJwUWUHlxzm6iHFPCC05Fwu0ftVp12_BQ3QRa29x2kHQA4zJGRxT0Am239h5PHQ6OT8ecJilSXsDuBv9Fpt5DZforNVdhKu_uUTvjw9vq3W2eXl6Xt1vMjPdSxkTsmIgC9Paavq5sqVmUgvGGqYFN5o2tq1FK1qoTcV1Y5jkhRCmAEtbKwlfoptj7hD6zxFiUgcXDXSd9tCPUbGSS0ZkQegk5UepCX2MAVo1BHfQ4VtRomZuaq9-uamZmzpym1x3RxdMLb4cBBWNg6midQFMUrZ3__p_AFFWeMs</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Lv, Panpan</creator><creator>Man, Shuli</creator><creator>Xie, Lu</creator><creator>Ma, Long</creator><creator>Gao, Wenyuan</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202108</creationdate><title>Pathogenesis and therapeutic strategy in platinum resistance lung cancer</title><author>Lv, Panpan ; Man, Shuli ; Xie, Lu ; Ma, Long ; Gao, Wenyuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-26972e94cfd7bbc7d5a29a622b2a63ca1bdf86f6fe8c73abc293466c4ed1fd903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Chemoresistance</topic><topic>Lung cancer</topic><topic>Platinum</topic><topic>Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lv, Panpan</creatorcontrib><creatorcontrib>Man, Shuli</creatorcontrib><creatorcontrib>Xie, Lu</creatorcontrib><creatorcontrib>Ma, Long</creatorcontrib><creatorcontrib>Gao, Wenyuan</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochimica et biophysica acta. Reviews on cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lv, Panpan</au><au>Man, Shuli</au><au>Xie, Lu</au><au>Ma, Long</au><au>Gao, Wenyuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathogenesis and therapeutic strategy in platinum resistance lung cancer</atitle><jtitle>Biochimica et biophysica acta. Reviews on cancer</jtitle><date>2021-08</date><risdate>2021</risdate><volume>1876</volume><issue>1</issue><spage>188577</spage><epage>188577</epage><pages>188577-188577</pages><artnum>188577</artnum><issn>0304-419X</issn><eissn>1879-2561</eissn><abstract>Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents in clinical use both of lung cancer in mono-and combination therapies. However, platinum resistance limits its clinical application. It is necessary to understand the molecular mechanism of platinum resistance, identify predictive markers, and develop newer, more effective and less toxic agents to treat platinum resistance in lung cancer. Here, it summarizes the main molecular mechanisms associated with platinum resistance in lung cancer and the development of new approaches to tackle this clinically relevant problem. Moreover, it could lead to the development of more effective treatment for refractory lung cancer in future.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.bbcan.2021.188577</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-419X |
| ispartof | Biochimica et biophysica acta. Reviews on cancer, 2021-08, Vol.1876 (1), p.188577-188577, Article 188577 |
| issn | 0304-419X 1879-2561 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2539209401 |
| source | ScienceDirect Journals (5 years ago - present) |
| subjects | Chemoresistance Lung cancer Platinum Therapy |
| title | Pathogenesis and therapeutic strategy in platinum resistance lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T19%3A54%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathogenesis%20and%20therapeutic%20strategy%20in%20platinum%20resistance%20lung%20cancer&rft.jtitle=Biochimica%20et%20biophysica%20acta.%20Reviews%20on%20cancer&rft.au=Lv,%20Panpan&rft.date=2021-08&rft.volume=1876&rft.issue=1&rft.spage=188577&rft.epage=188577&rft.pages=188577-188577&rft.artnum=188577&rft.issn=0304-419X&rft.eissn=1879-2561&rft_id=info:doi/10.1016/j.bbcan.2021.188577&rft_dat=%3Cproquest_cross%3E2539209401%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2539209401&rft_id=info:pmid/&rft_els_id=S0304419X21000743&rfr_iscdi=true |